Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
Public ClinicalTrials.gov record NCT01087502. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Study identification
- NCT ID
- NCT01087502
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Interventions
- Glimepiride Drug
- Placebo Drug
- Linagliptin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Apr 30, 2012
- Completion
- Not listed
- Last update posted
- Jun 26, 2014
Started 2010
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.64.10007 Boehringer Ingelheim Investigational Site | Chula Vista | California | — | — |
| 1218.64.10018 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1218.64.10016 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1218.64.10015 Boehringer Ingelheim Investigational Site | Boise | Idaho | — | — |
| 1218.64.10002 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.64.10004 Boehringer Ingelheim Investigational Site | Flint | Michigan | — | — |
| 1218.64.10006 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1218.64.10003 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 1218.64.10013 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1218.64.10020 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1218.64.10008 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1218.64.10009 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 1218.64.10005 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.64.10011 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1218.64.10014 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1218.64.10010 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01087502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01087502 live on ClinicalTrials.gov.